SCPH scPharmaceuticals Inc.

8.87
+0.09  (+1%)
Previous Close 8.78
Open 8.98
Price To Book 3.62
Market Cap 186,109,276
Shares 20,981,880
Volume 21,353
Short Ratio
Av. Daily Volume 97,379
Stock charts supplied by TradingView

NewsSee all news

  1. scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update

    Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Initiating FUROSCIX pre-commercialization and product positioning efforts Strong balance sheet; ending 2019 with $72.8 million in

  2. scPharmaceuticals Inc. to Present at the Cowen and Company's 40th Annual Health Care Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce

  3. scPharmaceuticals Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce

  4. scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce

  5. scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference

    BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 planned.
scCeftriaxone
Infections caused by gram-positive and gram-negative organisms
CRL issued June 13, 2018. NDA to be refiled mid-2020.
Furoscix
Heart failure
NDA filing due 2021.
Ceftriaxone
Baceteria infections

Latest News

  1. scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update

    Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Initiating FUROSCIX pre-commercialization and product positioning efforts Strong balance sheet; ending 2019 with $72.8 million in

  2. scPharmaceuticals Inc. to Present at the Cowen and Company's 40th Annual Health Care Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce

  3. scPharmaceuticals Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce

  4. scPharmaceuticals Inc. to Present at the Piper Jaffray 31st Annual Healthcare Conference

    scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce

  5. scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference

    BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of

  6. scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies Completed $20.0

  7. scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement

    Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank BURLINGTON, Mass.,